NCT00791895View on ClinicalTrials.gov

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 26, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

November 29, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Treat-to-target dose titration scheme

Trial Locations (15)

12206

Novo Nordisk Investigational Site, Albany

32720

Novo Nordisk Investigational Site, DeLand

38119

Novo Nordisk Investigational Site, Memphis

44115

Novo Nordisk Investigational Site, Cleveland

53209

Novo Nordisk Investigational Site, Milwaukee

67205

Novo Nordisk Investigational Site, Wichita

68114

Novo Nordisk Investigational Site, Omaha

75231

Novo Nordisk Investigational Site, Dallas

77030

Novo Nordisk Investigational Site, Houston

84403

Novo Nordisk Investigational Site, Ogden

85006

Novo Nordisk Investigational Site, Phoenix

97504

Novo Nordisk Investigational Site, Medford

98057

Novo Nordisk Investigational Site, Renton

92093-0694

Novo Nordisk Investigational Site, La Jolla

92093-0831

Novo Nordisk Investigational Site, La Jolla

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY